Nuvation Bio Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation

Reuters

11/04

<a href="https://laohu8.com/S/NUVB">Nuvation Bio</a> Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation

Nuvation Bio Inc. has provided an update highlighting recent developments across its oncology portfolio. The company reported that IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor, received approval in the U.S., Japan, and China for advanced ROS1-positive non-small cell lung cancer (NSCLC), with 204 new patient starts in Q3 2025. Safusidenib, a brain-penetrant mIDH1 inhibitor, is entering a pivotal study for high-grade IDH1-mutant glioma, with plans to potentially include high-risk, low-grade patients. NUV-1511, a clinical-stage drug-drug conjugate, is in Phase 1/2 evaluation, while NUV-868, a BD2-selective BET inhibitor, has completed Phase 1 and Phase 1b studies. The company reported a cash balance of $549 million as of September 30, 2025, with additional funding available under a term loan agreement. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2580226320"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580226320\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580226320?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 05:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580226320","market":"nz","top_or_hot":-1,"title":"Nuvation Bio Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NUVB.WS\">Nuvation Bio</a> Inc. has provided an update highlighting recent developments across its oncology portfolio. The company reported that IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor, received approval in the U.S., Japan, and China for advanced ROS1-positive non-small cell lung cancer (NSCLC), with 204 new patient starts in Q3 2025. Safusidenib, a brain-penetrant mIDH1 inhibitor, is entering a pivotal study for high-grade IDH1-mutant glioma, with plans to potentially include high-risk, low-grade patients. NUV-1511, a clinical-stage drug-drug conjugate, is in Phase 1/2 evaluation, while NUV-868, a BD2-selective BET inhibitor, has completed Phase 1 and Phase 1b studies. The company reported a cash balance of $549 million as of September 30, 2025, with additional funding available under a term loan agreement. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvation Bio Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvation Bio Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 05:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NUVB.WS\">Nuvation Bio</a> Inc. has provided an update highlighting recent developments across its oncology portfolio. The company reported that IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor, received approval in the U.S., Japan, and China for advanced ROS1-positive non-small cell lung cancer (NSCLC), with 204 new patient starts in Q3 2025. Safusidenib, a brain-penetrant mIDH1 inhibitor, is entering a pivotal study for high-grade IDH1-mutant glioma, with plans to potentially include high-risk, low-grade patients. NUV-1511, a clinical-stage drug-drug conjugate, is in Phase 1/2 evaluation, while NUV-868, a BD2-selective BET inhibitor, has completed Phase 1 and Phase 1b studies. The company reported a cash balance of $549 million as of September 30, 2025, with additional funding available under a term loan agreement. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NUVB","symbol_name":"Nuvation Bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL790fV4:1","article_id":"2580226320","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580226320","pubTimestamp":1762206270,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nuvation Bio Inc. has provided an update highlighting recent developments across its oncology portfolio. The company reported that IBTROZI , a next-generation ROS1 inhibitor, received approval in the U.S., Japan, and China for advanced ROS1-positive non-small cell lung cancer , with 204 new patient starts in Q3 2025. Safusidenib, a brain-penetrant mIDH1 inhibitor, is entering a pivotal study for high-grade IDH1-mutant glioma, with plans to potentially include high-risk, low-grade patients. NUV-1511, a clinical-stage drug-drug conjugate, is in Phase 1/2 evaluation, while NUV-868, a BD2-selective BET inhibitor, has completed Phase 1 and Phase 1b studies. The company reported a cash balance of $549 million as of September 30, 2025, with additional funding available under a term loan agreement. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NUVB":"Nuvation Bio, Inc.","BK4007":"制药"},"translate_title":"Nuvation Bio在公司演示中强调了突破性的肿瘤学进展和IBTROZI的推出","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUVB":0.9},"content_text":"Nuvation Bio Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation\n    \n\nNuvation Bio Inc. has provided an update highlighting recent developments across its oncology portfolio. The company reported that IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor, received approval in the U.S., Japan, and China for advanced ROS1-positive non-small cell lung cancer (NSCLC), with 204 new patient starts in Q3 2025. Safusidenib, a brain-penetrant mIDH1 inhibitor, is entering a pivotal study for high-grade IDH1-mutant glioma, with plans to potentially include high-risk, low-grade patients. NUV-1511, a clinical-stage drug-drug conjugate, is in Phase 1/2 evaluation, while NUV-868, a BD2-selective BET inhibitor, has completed Phase 1 and Phase 1b studies. The company reported a cash balance of $549 million as of September 30, 2025, with additional funding available under a term loan agreement. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}